Skip to main content
OpenTrials
Completed

NCT Number: NCT01179789

New E-Service for a Dietary Approach to the Elderly

Ageing of the population is a major event in the world. Gerontological/geriatric literature unanimously indicate that physical exercise and diet are at present the two available fundamental approaches to contrast/prevent most of the age associated alterations. In the elderly the inflammageing, the oxidative stress and the alteration of the intestinal microbiota can be influenced by nutritional status and possibly corrected by an appropriate dietetic intervention:

Nowadays the nutraceutical food supplements become an opportunity for the consumer to improve the quality of individual diet for specific needs

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

65 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Charité - Universitätsmedizin Berlin

Berlin, 10117, Germany

About this study

Ageing of the population is a major event in the world. Gerontological/geriatric literature unanimously indicate that physical exercise and diet are at present the two available fundamental approaches to contrast/prevent most of the age associated alterations. In the elderly the inflammageing, the oxidative stress and the alteration of the intestinal microbiota can be influenced by nutritional status and possibly corrected by an appropriate dietetic intervention:

Nowadays the nutraceutical food supplements become an opportunity for the consumer to improve the quality of individual diet for specific needs

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: from 65 to 85 years
  • Body Mass Index: 22-30 kg/m2
  • ECOG Performance status: WHO performance score 0 to 2
  • Absence of known diseases and/or abnormalities of haematological parameters (haematological, inflammatory, metabolic, hepatic and renal diseases)
  • The subjects must be able to comply with management of nutraceutical products and with scheduled follow-up
  • The subjects must be able to use the computer and to access to the web, by themselves or with the help of a caregiver

Exclusion criteria

  • History of significant neurologic or psychiatric disorders including dementia, seizures, bipolar disorder
  • Geriatric anorexia [less than 2 full meals per day and /or less than one serving of dairy products (milk, cheese, yogurt) per day or two or more servings of legumes or eggs per week or one serving of meat, fish or poultry every day]
  • Weight loss > 5% in the last month
  • Previous antibiotic treatment within 4 months
  • Active infection requiring per OS or IV antibiotics, including active tuberculosis, known and declared HIV, HCV
  • Constipation and/or abdominal pain/discomfort that require dietary supplements or medical therapy
  • Gastric disease that requires medical therapy (e.g. gastric secretion inhibitory drugs)
  • Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis, diverticulosis, diverticulitis)
  • Diabetes mellitus
  • Dislipidemia and/or any metabolic disease that requires medical or dietetic treatment
  • Myocardial infarction within 6 months prior to study entry, congestive heart disease, uncontrolled cardiac insufficiency, and any current grade 3 or 4 cardio-vascular disorder despite treatment
  • Current history of neoplasm except for curatively treated non melanoma skin cancer or in situ carcinoma of the cervix and except for other cancer curatively treated and with no evidence of disease for at least 5 years
  • Other sever underlying medical conditions, which could impair the ability of the patient to participate in the study
  • Chronic anti-inflammatory therapy with FANS or previous therapy within 20 days from the beginning of the study. The occasional use of anti-inflammatory therapy is not an exclusion criteria, but the use is not allowed within 3 days before the analysis and for more than 8 days/2 months during the study
  • Previous (within 15 days) or concomitant treatment that modifies intestinal absorption (e.g. metformin, acarbose in diabetic treatment…)
  • Probiotics, prebiotics or symbiotics (yogurt or another functional foods) intake in the last 3 weeks
  • Use of food supplements or functional foods such as probiotics, prebiotics, symbiotics, vitamins and minerals different than whose established in this study, is not allowed during the study period or previously within 1 week (except for vitamin D, calcium, vitamin B12)
  • Total parenteral nutrition within 4 months
  • History of allergy to one of the excipients present in the products under evaluation
  • Concomitant or within 4 week period administration of any experimental drug, food supplements or nutraceuticals under investigation
  • Subjects clearly intending to withdraw from the study if not randomised in a given arm, or subjects who cannot be regularly followed up for psychological, social, familial or geographic reasons
  • Subjects with expected non-compliance to protocol guidelines

Treatment and study plan

Optimal Diet

Behavioral

a dietician will train each subject (or the caregiver) to use the personalized diet on web platform

VSL#3®

Dietary Supplement

probiotic blend Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water

AISA-5203-L

Dietary Supplement

fruit extracted terpene Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water

Argan oil

Dietary Supplement

Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water

Primary outcomes

  1. High-sensitivity C-reactive protein (hs-CRP) as measure of systemic low-grade inflammation (cardiovascular risk)

    Time frame: 2 months

Secondary outcomes

  1. Inflammageing status as measure of ageing-associated inflammatory processes

    Time frame: 2 months

    WBC, hemoglobin, erythrocyte sedimentation rate, fibrinogen, total cholesterol, triglycerides, insulin, glucose, IL-6, TNFα, IL-10, TGF-1, IGF-1, adiponectin, leptin, homocysteine, folic acid and vitamin B12

  2. Oxidative stress

    Time frame: 2 months

    Plasma total antioxidant capacity by TEAA (Trolox Equivalent Antioxidant Activity), glutathione , superoxide dismutase, glutathione peroxidase, glutathione reductase, catalase activities

  3. Gut micobiota

    Time frame: 2 months

    Expression of 16S ribosomal RNA bacterial groups from feces by RT-PCR. Ratio between lactobacilli and clostridia bacteria as measure of impact of personalized nutrition with and without nutraceuticals on gut microbiota.

  4. Quality of life (QoL)

    Time frame: 2 months

    Daily visual analogue scale, SF-36 and General Health Questionnaire (GHQ) as direct measures of QoL. ECOG performance status, IADL, Spielberger Anxiety Index (SAI), and CED-D scale as indirect measures of quality of life.

  5. Physical performance status

    Time frame: 2 months

    Short physical performance battery (SBBP), muscle function (hand-grip dynamometry, and physical activity level (IPAQ).

  6. Compliance

    Time frame: 2 months

    Daily visual analogue scales as measures of compliance to web diet advices and to the nutraceutical intake.

Sponsors and collaborators

Lead sponsor

Charite University, Berlin, Germany

Other

Registry information

Official study title

Open Label, Randomized Study of the Impact of Diet on Gut Microbiota, Inflammageing and Oxidative Stress in Elderly People. Potential Benefits of Dietary Advices Alone or Associated to Nutraceutical Food Supplements Argan Oil, VSL#3 Probiotic Blend, 5203-L Fruit Extract Terpene. German Part of a Multicentric European Study

Acronym: RISTOMED

Important dates

Study start
2009
Primary completion
2010
Study completion
2011
First posted
Aug 11, 2010
Registry last updated
Oct 31, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.